Multiparametric In-vitro Cardiotoxicity Testing Market Size is Expected to Grow at a CAGR of 13.9% by 2031

The Multiparametric In-vitro Cardiotoxicity Testing Market focuses on laboratory-based assays, screening platforms, and testing methodologies aimed at assessing the cardiotoxic effects of pharmaceutical compounds, environmental chemicals, and therapeutic agents using in-vitro models and predictive toxicology approaches. This research report aims to provide an in-depth analysis of the market dynamics, technological advancements, key players, recent developments, and future prospects within the multiparametric in-vitro cardiotoxicity testing sector.

Multiparametric In-vitro Cardiotoxicity Testing market is estimated to attain a valuation of US$ 166.5 Mn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 13.9% during the forecast period, 2022-2031

Get a Sample Copy of the Multiparametric In-vitro Cardiotoxicity Testing Market Research Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85319

The significant players operating in the global Multiparametric In-vitro Cardiotoxicity Testing market are

Creative Bioarray, Agilent Technologies, Inc., Hemogenix Inc., Merck KGaA, Molecular Devices, LLC., Evotec, Miltenyi Biotec, FUJIFILM Cellular Dynamics, Enzo Life Sciences, Inc., Axol Bioscience Ltd., Stemina Biomarker Discovery, Inc., Eurofins Discovery, and emka TECHNOLOGIES.

Market Dynamics

Drug Safety Assessment: Regulatory agencies require comprehensive cardiac safety assessments for pharmaceutical compounds in preclinical and clinical development to identify potential cardiotoxic effects, assess proarrhythmic risk, and inform risk-benefit evaluations for drug approval and marketing authorization.

Advancements in Testing Technologies: Technological innovations, high-content screening platforms, microfluidic devices, induced pluripotent stem cell (iPSC) technology, and multi-electrode array (MEA) systems enable the development of multiparametric in-vitro assays with improved sensitivity, throughput, and predictive value for cardiotoxicity testing.

Cost and Time Savings: In-vitro cardiotoxicity testing offers advantages such as reduced reliance on animal models, lower costs, faster turnaround times, and increased throughput compared to traditional in-vivo studies, facilitating early-stage compound screening, lead optimization, and safety profiling in drug discovery and development.

Buy this Premium Research Report: - https://www.transparencymarketresearch.com/checkout.php?rep_id=85319<ype=S

Testing Modalities

Multiparametric in-vitro cardiotoxicity testing encompasses a variety of assays and platforms, including:

Ion Channel Assays: Assessing the effects of compounds on cardiac ion channels such as hERG (human ether-a-go-go-related gene) potassium channels, sodium channels, calcium channels, and potassium channel blockade using patch clamp, automated electrophysiology, and fluorescence-based assays.

Contractility Assays: Measuring changes in cardiomyocyte contractility, beating frequency, and sarcomere function using video microscopy, impedance-based assays, microelectrode arrays, and force sensors to evaluate drug-induced changes in cardiac function and contractile parameters.

Biomarker Panels: Analyzing circulating biomarkers such as troponins, brain natriuretic peptide (BNP), cardiac troponin I (cTnI), creatine kinase-MB (CK-MB), and lactate dehydrogenase (LDH) released from damaged cardiomyocytes as indicators of cardiac injury and myocardial damage.

Recent Developments

Organ-on-a-Chip Platforms: Microphysiological systems, organ-on-a-chip devices, and 3D tissue models recapitulate human cardiac physiology, cellular interactions, and tissue architecture, providing more physiologically relevant in-vitro models for cardiotoxicity testing and drug safety assessment.

Integration of Omics Technologies: Transcriptomics, proteomics, metabolomics, and high-throughput screening platforms enable the identification of molecular signatures, pathway perturbations, and toxicity biomarkers associated with drug-induced cardiotoxicity, enhancing mechanistic insights and predictive modeling capabilities.

Market Segmentation -

Type of Assay
Calcium Transient Assay
Cardiac Marker Detection
hERG Assay
Multi-ion Channel Assay
Others

End-user
Contract Research Organizations (CROs)
Pharmaceutical and Biotech Companies
Others

This Report lets you identify the opportunities in Multiparametric In-vitro Cardiotoxicity Testing Market by means of a region:

North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

Key Features of the Multiparametric In-vitro Cardiotoxicity Testing Market Report: -

➤ Analyze competitive developments such as expansions, deployments, new product launches, and market acquisitions.

➤ Examine the market opportunities for stakeholders by identifying higher growth sections.

➤ To study and analyze the global Multiparametric In-vitro Cardiotoxicity Testing industry status and forecast including key regions.

➤ An in-depth analysis of key product segments and application spectrum, providing strategic recommendations to incumbents and new entrants to give them a competitive advantage over others.

➤ It provides a comprehensive analysis of key regions of the industry as well as a SWOT analysis and Porter's Five Forces analysis to provide a deeper understanding of the market.

➤ It helps you make strategic business decisions and investment plans.

More Trending Reports by Transparency Market Research -

Spout Pouch Market- https://www.globenewswire.com/en/news-release/2024/03/05/2840558/32656/en/Spout-Pouch-Market-Expands-and-Approaching-USD-4-7-billion-by-2032-with-a-CAGR-of-4-6-Says-Transparency-Market-Research-Inc.html

Well Testing Services Market- https://www.globenewswire.com/en/news-release/2024/03/05/2840613/32656/en/Well-Testing-Services-Market-Expected-to-Hit-US-13-3-billion-by-2031-with-a-Growth-Rate-of-6-4-CAGR-Transparency-Market-Research-Inc.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.